Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | S100A4 | P26447 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29842916 | 1.00 | ALDH1A1 (0.47) | ALDH1A1TSHRTDP1GPR35HPGD | |
| SCHEMBL12648507 | 0.83 | TDP1 (0.50) | ALDH1A1TSHRTDP1GPR35HPGD | |
| SCHEMBL961175 | 0.81 | ALDH1A1 (0.52) | ALDH1A1TSHRTDP1GPR35HPGD | |
| SCHEMBL17141360 | 0.81 | ALDH1A1 (0.67) | ALDH1A1TSHRTDP1GPR35HPGD | |
| SCHEMBL5237985 | 0.81 | ALDH1A1 (0.50) | ALDH1A1TSHRTDP1GPR35HPGD | |
| SCHEMBL14983803 | 0.81 | TDP1 (0.44) | ALDH1A1TSHRTDP1GPR35HPGD | |
| SCHEMBL30100131 | 0.80 | ALDH1A1 (0.64) | ALDH1A1TSHRTDP1HPGDHSD17B10 | |
| SCHEMBL70062 | 0.80 | ALDH1A1 (0.64) | ALDH1A1TSHRTDP1HPGDHSD17B10 | |
| SCHEMBL28901826 | 0.80 | ALDH1A1 (0.46) | ALDH1A1TSHRTDP1GPR35HPGD | |
| SCHEMBL3010961 | 0.80 | TDP1 (0.61) | ALDH1A1TSHRTDP1GPR35SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958809-B2 | Salt of omecamtiv mecarbil and process for preparing salt | CYTOKINETICS, INC. (US) | 2024-04-16 | — | — | US | claimed |
| EP-4305018-A2 | SYNTHESIS OF OMECAMTIV MECARBIL | Amgen Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| CN-117157274-A | Synthesis of olmesartan Mo Kabi mol | 安进股份有限公司 | 2023-12-01 | — | — | CN | claimed |
| US-20230373955-A1 | SYNTHESIS OF OMECAMTIV MECARBIL | AMGEN INC. | 2023-11-23 | — | — | US | claimed |
| US-11702380-B2 | Synthesis of omecamtiv mecarbil | AMGEN INC. (US) | 2023-07-18 | — | — | US | claimed |
| CN-110799503-B | Synthesis of Meicartine | 美国安进公司 | 2023-06-27 | — | — | CN | claimed |
| US-20220298099-A1 | SYNTHESIS OF OMECAMTIV MECARBIL | AMGEN INC. | 2022-09-22 | — | — | US | claimed |
| WO-2022192414-A2 | SYNTHESIS OF OMECAMTIV MECARBIL | AMGEN INC. (US) | 2022-09-15 | — | — | WO | claimed |
| US-20220153700-A1 | SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT | CYTOKINETICS, INC. | 2022-05-19 | — | — | US | claimed |
| US-11040956-B2 | Synthesis of omecamtiv mecarbil | AMGEN INC. (US) | 2021-06-22 | — | — | US | claimed |
| EP-3645518-B1 | SYNTHESIS OF OMECAMTIV MECARBIL | AMGEN INC (US) | 2021-05-19 | — | — | EP | claimed |
| US-20200308143-A1 | SYNTHESIS OF OMECAMTIV MECARBIL | AMGEN INC. | 2020-10-01 | — | — | US | claimed |
| EP-3645518-A1 | SYNTHESIS OF OMECAMTIV MECARBIL | Amgen Inc. (US) | 2020-05-06 | — | — | EP | claimed |
| CN-110799503-A | Synthesis of mecamitocainide | 美国安进公司 | 2020-02-14 | — | — | CN | claimed |
| WO-2019006231-A1 | SYNTHESIS OF OMECAMTIV MECARBIL | AMGEN INC. (US) | 2019-01-03 | — | — | WO | claimed |
| US-12583821-B2 | Salt of omecamtiv mecarbil and process for preparing salt | CYTOKINETICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4698520-A1 | RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF | Gandeeva Therapeutics, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-1982982-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-10-22 | — | — | EP | disclosed |
| EP-1761520-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006009741-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308143-A1 | SYNTHESIS OF OMECAMTIV MECARBIL | SI, DPYD, MTHFD2 | ALDH1A1 547/4885TSHR 4409/4885TDP1 3924/4885 |
| US-11040956-B2 | Synthesis of omecamtiv mecarbil | SI, DPYD, MTHFD2 | ALDH1A1 547/4885TSHR 4409/4885TDP1 3924/4885 |
| US-11702380-B2 | Synthesis of omecamtiv mecarbil | SI, MTHFD2, DPYD | ALDH1A1 1017/4885TSHR 4312/4885TDP1 3903/4885 |
| US-20220153700-A1 | SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT | SI, SLC5A6, SLC28A1 | ALDH1A1 1835/4885TSHR 4307/4885TDP1 3853/4885 |
| US-20230373955-A1 | SYNTHESIS OF OMECAMTIV MECARBIL | DPYD, SI, MTHFD2 | ALDH1A1 570/4885TSHR 4415/4885TDP1 3895/4885 |
| US-20220298099-A1 | SYNTHESIS OF OMECAMTIV MECARBIL | SI, MTHFD2, DPYD | ALDH1A1 1017/4885TSHR 4312/4885TDP1 3903/4885 |
| US-12583821-B2 | Salt of omecamtiv mecarbil and process for preparing salt | SLC28A2, SLC28A1, SLC5A11 | ALDH1A1 1521/4885TSHR 2392/4885TDP1 3475/4885 |
| US-11958809-B2 | Salt of omecamtiv mecarbil and process for preparing salt | SI, SLC5A6, SLC28A1 | ALDH1A1 1835/4885TSHR 4307/4885TDP1 3853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.